Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2915
https://www.valueinhealthjournal.com/article/S1098-3015(17)33249-7/fulltext
Title :
Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33249-7&doi=10.1016/j.jval.2017.08.2915
First page :
A931
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2684